Tuesday, October 05, 2021 4:14:00 PM
Name and Principal Position
Dr. Cameron Durrant
Chairman and Chief Executive Officer
Dr. Dale Chappell
Chief Scientific Officer
Dr. Adrian Kilcoyne
Chief Medical Officer
Edward Jordon
Chief Commercial Officer
Number of Shares Underlying Grant (#)(1)
17,660 22,626 5,863 4,966
4th Quarter Base Salary Paid in Stock Options (percentage of quarterly amount)
$79,959 (50%) $102,433 (100%) $26,646 (25%) $22485 (25%)
(1) All options granted have an exercise price equal to $5.93, the closing price of Humanigen’s common stock on the September 30, 2021 grant date, and vest in three ratable installments on each of October 31, 2021, November 30, 2021 and December 31, 2021.
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM